LONDON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today ...
LONDON, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today ...
Additional Data Demonstrate Dose-Dependent Increase in Bone Strength Stiffness and Failure Load at the Radius as Measured by Finite Element Analysis, a Second Prespecified Primary Endpoint, Reaching ...
LONDON and REDWOOD CITY, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or the “Company” or the “Group,” a clinical stage biopharmaceutical ...
Oncologie receives exclusive global license to develop and commercialize navicixizumab “We believe Oncologie is expertly positioned to further advance navicixizumab through clinical development and ...
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) and Mereo BioPharma Group plc (NASDAQ:MREO) released interim data from the Phase 2 portion of the Phase 2/3 Orbit study of setrusumab. The data demonstrated ...
AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of “a-” (Excellent) of Mereo Insurance Limited (Mereo) (Hamilton, Bermuda). The outlook of ...
Mereo Insurance Commences Underwriting Everen Specialty Ltd’s (ESL) Excess Energy Casualty Portfolio
Effective June 1st 2026, Mereo Insurance Ltd has commenced underwriting the first Excess Casualty Energy policies under a renewal rights transaction undertaken between Everen and Cedar Trace, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results